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Abstract:
 
COPD is now widely recognized as a complex heterogeneous syndrome, having both 
pulmonary and extrapulmonary features. In clinical practice, the diagnosis of COPD is based 
on the presence of chronic airflow limitation, as assessed by post-bronchodilator spirometry. 
The severity of the airflow limitation, as measured by percent predicted FEV
1
, provides impor-
tant information to the physician to enable optimization of management. However, in order 
to accurately assess the complexity of COPD, there need to be other measures made beyond 
FEV
1
. At present, there is a lack of reliable and simple blood biomarkers to confirm and further 
assess the diagnosis of COPD. However, it is possible to identify patients who display differ-
ent phenotypic characteristics of COPD that relate to clinically relevant outcomes. Currently, 
validated phenotypes of COPD include alpha-1 antitrypsin deficiency, and “frequent exacer-
bators”. Recently, a definition and assessment of a new phenotype comprising patients with 
overlapping features of asthma and COPD has been suggested and is known as “asthma COPD 
overlap syndrome”. Several other phenotypes have been proposed, but require validation against 
clinical outcomes. Defining phenotypes requires the assessment of multiple factors indicating 
disease severity, its impact, and its activity. Recognition and validation of COPD phenotypes 
has an important role to play in the selection of evidence-based targeted therapy in the future 
management of COPD, but regardless of the diagnostic terms, patients with COPD should be 
assessed and treated according to their individual treatable characteristics.
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Introduction
COPD is now widely recognized as a complex heterogeneous syndrome with pul-
monary and extrapulmonary features.1,2 In the assessment of patients with COPD, it 
is important to identify clinical traits or phenotypes that may have consequences for 
the choice of treatment.1,3
The aim of this article is to discuss the challenges of accurately diagnosing and 
assessing COPD, to present the evidence for the importance of defining COPD phe-
notypes, and to provide guidance on how these phenotypes could be assessed. Rather 
than presenting a systematic review of the literature, we aim to debate and discuss 
the current status of COPD diagnosis, the proposed COPD phenotypes, and the dif-
ficulties and relevance of differentiating between asthma, COPD, and asthma COPD 
overlap syndrome (ACOS).
Importance of a correct diagnosis
An accurate diagnosis guides the physician to identify the most appropriate manage-
ment strategy. In particular, assessment of symptoms in asthma, COPD, and ACOS 
is crucial to achieving an accurate diagnosis.
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Prior to diagnosis, many patients with COPD may not 
recognize their symptoms as being due to a disease, since 
breathlessness may be attributed to aging, and cough and 
sputum production may be considered a consequence of 
smoking. An accurate diagnosis may help patients accept that 
they have COPD and to take action to change their lifestyle 
and help manage their symptoms.4
How to diagnose COPD
According to the most recent Global initiative for chronic 
Obstructive Lung Disease (GOLD) strategy for diagnosis 
and management of COPD, a diagnosis of COPD should be 
considered in any patient with symptoms of dyspnea, chronic 
cough or sputum production, and a history of risk factors 
for COPD (particularly tobacco smoking). Spirometry is 
mandatory to confirm the presence of persistent airflow 
limitation, a defining, but not a pathognomonic character-
istic of COPD.
Fev1
The standard diagnostic definition of persistent airflow 
limitation is a post-bronchodilator ratio of forced expira-
tory volume in 1 second to forced vital capacity (FEV
1
/
FVC) of 0.7.2 However, this definition will underes-
timate the presence of COPD in younger patients and 
overestimate its presence in older patients, in whom 
airflow limitation may simply be a result of advancing 
age.5,6 This is especially true for mild disease, where 
75% of patients aged 65 years and meeting the GOLD 
1 criteria for airflow limitation have been shown to have 
FEV
1
/FVC values that lie within the normal range for 
healthy age-related and race-matched controls.5 Estab-
lishing the lower limit of “normal” is highly dependent 
on the reference population and has not been validated 
in longitudinal studies. Thus, due to its simplicity and 
validation in many studies, the fixed FEV
1
/FVC ratio has 
remained the diagnostic criterion for the clinical situation, 
whereas the lower limit of normal has been advocated for 
use in epidemiological studies.
Beyond Fev1
In an effort to improve the management of patients with 
COPD and encourage a more comprehensive assessment 
of patients, the GOLD guidelines were revised recently to 
include COPD categories based on a combined score for 
symptoms, degree of airflow limitation, risk of exacerbation, 
and presence of comorbidities (Table 1).2 However, compre-
hensive assessment in order to obtain a better understanding 
of the symptomatology in an individual patient should also 
include other parameters.
Resting inspiratory capacity
One of the functional consequences of the pathological 
changes that occur in COPD is over-inflation of the lungs.7 
Resting inspiratory capacity (IC) is an indirect but very pow-
erful and non-invasive measure of lung hyperinflation, and 
of the elastic load being exerted on the inspiratory muscles. 
IC decreases linearly with increasing airflow limitation8 and 
is sufficiently sensitive to signal airway obstruction even in 
mild disease when FEV
1
 is largely unaffected. Resting IC 
is considered a good indicator of the severity of COPD and, 
as a ratio with total lung capacity (TLC), predicts mortality 
and respiratory failure.9
During exercise in patients with COPD, end expiratory lung 
volume increases, IC and inspiratory reserve volume (IRV) 
both diminish, and further tidal volume expansion is limited 
as TLC is approached (Figure 1). In advanced COPD, the 
low IC means that the IRV reaches its minimal value (~0.5 L 
Table 1 COPD categories based on a combined score for symptoms, degree of airflow limitation, exacerbation risk, and presence of 
comorbidities
Patient Characteristic Spirometric  
classification
Exacerbations  
per year
COPD Assessment  
Test
mMRC score
A Low risk, 
less symptoms
GOLD 1–2 1a 10 0–1
B Low risk, 
more symptoms
GOLD 1–2 1a 10 2
C High risk, 
less symptoms
GOLD 3–4 2b 10 0–1
D High risk,
more symptoms
GOLD 3–4 2b 10 2
Notes: GOLD 1–2, mild‑moderate airflow limitation; GOLD 3–4, severe‑very severe airflow limitation; anot leading to hospital admission; b1 leading to hospital admission. 
From the Global Strategy for Diagnosis, Management and Prevention of COPD 2015, © Global Initiative for Chronic Obstructive Lung Disease (GOLD), all rights reserved. 
Available from http://www.goldcopd.org.2
Abbreviations: GOLD, Global initiative for chronic Obstructive Lung Disease; mMRC, modified Medical Research Council.
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below TLC) at low exercise intensities; further increases in 
ventilation become impossible and exercise is terminated. 
During exercise, the central drive to breathe continues to 
increase, but the ability of the respiratory muscles to respond 
to this drive progressively diminishes because of the effects 
of dynamic lung hyperinflation (critical reduction in IRV). 
It follows that a much greater respiratory effort is required to 
generate the same tidal volume as at rest, thereby leading to 
intolerable shortness of breath. IC at rest is therefore a good 
predictor of maximal ventilatory capacity and a patient’s 
ability to exercise. Increasing IC with bronchodilators is 
associated with reduced dyspnea ratings and improved 
exercise tolerance.10
Field and laboratory exercise tests
The impact of COPD on a patient’s functional capacity 
in relation to exercise can be explored using the 6-minute 
walking distance (6MWD) test. This test is simple to 
perform, correlates well with peak oxygen uptake, and 
is a good index of functional disability. It relates to daily 
activities and has predictive value in relation to health 
status and survival, but not hospitalizations for COPD 
exacerbations.11–13 The shuttle walking test is an alternative 
to the 6MWD test and is perhaps more responsive to the 
effect of training.14
Another method of measuring the functional impact 
of COPD is to use cardiopulmonary exercise testing. This 
requires more equipment than other field tests, and provides 
a measure of the integrated function of the respiratory, 
cardiocirculatory, peripheral muscle, and neurosensory sys-
tems under stress. It accurately quantifies abnormalities in 
pulmonary gas exchange, ventilatory demand, and dynamic 
respiratory mechanics and their sensory consequences. Fur-
thermore, peak oxygen uptake measured during incremental 
exercise tests has prognostic value in relation to survival in 
COPD.15
Chest computed tomography scanning
Thoracic computed tomography (CT) scanning can be used 
to quantify the extent, type, distribution, and progression of 
emphysema;16,17 however, measurement of airway dimen-
sions using CT scanning has been more problematic.18,19 
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Figure 1 Comparison of pulmonary dynamics in health and COPD showing tidal pressure‑volume curves during rest (filled area) and exercise (open area).
Notes: Reproduced with permission of Taylor & Francis Ltd (http://www.tandfonline.com). O’Donnell De, Laveneziana P. The clinical importance of dynamic lung 
hyperinflation in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease. 2006;3(4):219–232.79
Abbreviations: eeLv, end-expiratory lung volume; IC, inspiratory capacity; IRv, inspiratory reserve volume; P, pressure; Rv, residual volume; TLC, total lung capacity; 
 v, volume.
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The presence of emphysema is associated with a more rapid 
decline in FEV
1
 and with increased mortality,20 and recent 
studies have shown relationships between both the extent 
of emphysema and airway thickening and the frequency of 
exacerbations.21–23 The distribution of emphysema has also 
been used to define a COPD phenotype, ie, upper lobe hetero-
geneous emphysema, as a clinical trait that shows improve-
ment in survival with lung volume reduction surgery.24 
In addition, chest CT scanning can aid the diagnosis of 
other lung conditions, such as bronchiectasis, obliterative 
bronchiolitis, and diffuse panbronchiolitis,2,6 and can be used 
to assess comorbidities such as coronary artery disease by 
measuring coronary artery calcification.25 CT scans have also 
proven useful for identifying patients with a mixed asthma/
COPD phenotype who have airway-predominant symptoms 
(as opposed to emphysema-predominant symptoms) and 
features of asthma.26
COPD phenotypes
The concept of a clinical COPD phenotype has been pro-
posed as 
a single or combination of disease attributes that describe 
differences between individuals with COPD as they relate 
to clinically meaningful outcomes like symptoms, exacer-
bations, response to therapy, rate of disease progression, 
or death.1
The goal of COPD phenotyping is to be able to classify 
patients into distinct subgroups according to prognosis and 
response to therapy in order to better select the appropriate 
therapy that can optimize clinically meaningful outcomes 
for patients.
What phenotypes have been proposed?
The ECLIPSE study of 2,164 patients with COPD has helped 
to expand our knowledge of several COPD phenotypes and 
identified potential biomarkers for predicting clinical out-
comes in these phenotypes.27
Prospective validation of COPD phenotypes against 
clinical outcomes or response to treatment is essential in 
defining a phenotype.1 At least three COPD phenotypes have 
been validated in this way. Alpha-1 antitrypsin deficiency is 
a genetic condition that predisposes patients to COPD and 
liver disease, and has been identified as a specific phenotype 
that may respond positively to augmentation therapy.28
A second validated phenotype, emphysema/hyperinflation, 
characterized by upper-lobe emphysema, dyspnea, and poor 
exercise capacity, is associated with severe airflow limitation. 
This phenotype appears to respond well to lung volume 
reduction surgery, which improves survival.24,29
Frequent exacerbators (2 per year), a third phenotype, 
have poor quality of life, increased mortality, and a greater 
decline in lung function.11,27,30 This phenotype is also asso-
ciated with high risk for gastroesophageal reflux disease 
and elevated white blood cell counts. Therapies that reduce 
the frequency of exacerbations are available and they also 
improve quality of life in this phenotype.31 On average, 
frequent exacerbators have more severe airway obstruction, 
with significantly higher values for the modified Medical 
Research Council dyspnea scale and increased Body mass 
index, airflow Obstruction, Dyspnea and Exercise (BODE) 
index compared with infrequent exacerbators.32,33
Several other potential phenotypes have been proposed, 
but are not yet fully validated against clinical outcomes. 
These include a phenotype of mild airway obstruction but 
disproportionately severe dyspnea; these patients may be 
detectable using tests for exercise performance and radio-
graphic imaging.34,35 A phenotype of rapid lung function 
decline has also been described, which appears to be indepen-
dently associated with severity of emphysema, as assessed 
by either CT or carbon monoxide transfer capacity.20,36 
Other phenotypes associated with poor prognoses, including 
increased mortality, have been reported, ie, a phenotype with 
comorbidities linked to poor outcomes (eg, heart disease, 
systemic and vascular disease, and anxiety and depressive 
disorders)37,38 and a phenotype with persistent inflammation, 
defined by ongoing elevation of blood inflammatory markers 
such as C-reactive protein, fibrinogen, and white blood cell 
count.39,40 The chronic bronchitis phenotype is also associ-
ated with poor outcomes. Compared with patients without 
chronic bronchitis, patients with this phenotype are more 
likely to be younger, male, Caucasian, have a greater extent 
of dyspnea, higher frequency of exacerbations, greater airway 
obstruction, and increased airway wall thickening, detect-
able both clinically and radiologically.41 This phenotype is 
also associated with a greater prevalence of cardiovascular 
comorbidities and sleep apnea syndrome than the emphysema 
and mixed asthma/COPD phenotypes.42
There are reports of a subgroup of COPD patients with 
chronic bacterial airway colonization who are at increased 
risk for frequent exacerbations, have higher levels of both 
airway and systemic inflammation, and are at increased risk 
of cardiovascular complications compared with those without 
chronic bacterial airway colonization.43
Some phenotypes describe COPD co-existing with other 
conditions. In the COPD/lung cancer phenotype, COPD 
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increases the risk for lung cancer, and patients with COPD 
at the time of lung cancer diagnosis have a poorer prognosis 
than those with lung cancer and no COPD.44
Patients with COPD may develop pulmonary hyperten-
sion, which is usually mild, but a specific phenotype with 
severe pulmonary hypertension disproportionate to the 
underlying COPD has been proposed.45,46 This phenotype 
is characterized by diffuse emphysema on high-resolution 
CT scans, severe precapillary pulmonary hypertension 
(40 mmHg), severely reduced carbon monoxide diffusion 
capacity, progressive dyspnea, and normal spirometry.46,47
A subgroup of patients with COPD has been identified 
as non-smokers who may have developed COPD following 
exposure to dust and fumes not related to smoking. These 
individuals are at greater risk for pneumonia but have no 
additional risk for cardiovascular comorbidities or all-cause 
mortality compared with non-smokers without airway 
obstruction.48
Although the overlap of symptoms between asthma and 
COPD has been recognized for many years, its characteriza-
tion as a separate phenotype has recently attracted much inter-
est due to the publication of a consensus statement by Global 
Initiative for Asthma (GINA) and GOLD on the diagnosis, 
assessment, and treatment of this condition.49 This phenotype 
is discussed in detail in the following section.
Differences between COPD 
and asthma
Key pathological and clinical differences
In many patients, asthma and COPD have typical clinical 
features that usually make the two diseases distinguishable. 
The clinical features of COPD are reduced lung function, with 
limited reversibility, emphysema, and sometimes cor pulmon-
ale and hypoxemia. Patients usually have a smoking history of 
many pack-years.50 In contrast, asthma is characterized in the 
majority of patients by lung function that can be normalized 
through good response to therapy, and can often be associated 
with atopy, rhinitis, and high exhaled nitric oxide.49,51
Although guidelines2,49 define both asthma and COPD 
as inflammatory disorders of the respiratory system, distinct 
inflammatory patterns exist, driven by different chemical 
mediators. A key histopathological difference is the destruc-
tion of alveolar walls in COPD that leads to emphysema.52 
Furthermore, the inflammation in the lungs is usually differ-
ent in both diseases; CD4+ T cells and eosinophils are the 
predominant cells in asthma, while CD8+ T cells and neu-
trophils predominate in COPD.52 However, there is a greater 
difference between the cellular profiles of either of these 
conditions compared with healthy individuals than between 
the profiles seen in asthma and COPD (Figure 2).52–54
While smoking is a key driver of lung function decline 
in COPD,27 allergens are the main protagonists in asthma; 
however, smoking also accelerates lung function decline in 
asthma.55 A multivariate analysis of individuals with asthma 
found a dose–response relationship between smoking and 
lung function decline, but a greater effect of the presence 
versus the absence of airway hyper-reactivity.56
Distinct phenotypes in asthma 
and COPD
Several COPD phenotypes based on predominant symptoms 
have been described in this article and specific interventions 
are available to improve patient outcomes.1 Distinct asthma 
phenotypes have also been characterized on the basis of aller-
gic status, the predominance of neutrophilic inflammation, late 
onset and persistent but reversible airflow limitation, degree of 
airway obstruction, atopic burden, and exacerbation history.57,58 
These asthma phenotypes are distinguishable on the basis of 
clinical attributes, such as the type and severity of symptoms, 
and appear to respond to therapy differently, but consistently 
within phenotypes.57,58 However, it must be borne in mind 
that theoretical phenotypes are not always mirrored in prac-
tice; patients with COPD are not only heterogeneous but also 
complex, and different clinical characteristics or phenotypes 
may occur in any given patient. Thus, a range of treatable traits 
may occur in an individual COPD patient.59
Similarities between asthma 
and COPD
Clinical and pathological similarities
Asthma and COPD are both inflammatory lung disorders that 
result in airflow limitation. In particular, tackling a diagnosis 
that differentiates asthma from COPD is sometimes chal-
lenging because they share many clinical and pathological 
similarities (Table 2).2,49,60,61 In addition, ACOS may cause 
further diagnostic difficulties since the clinical aspects 
of this overlap population are not well understood.49,61–63 
Consequently, unless it is clear from the patient history, a 
differential diagnosis with asthma may be difficult given 
that there is currently no single physiological test that can 
distinguish asthma and COPD.2
etiology
According to the “Dutch hypothesis”, asthma and COPD 
share a genetic basis, the expression of which is dependent 
on external factors such as age, sex, and environmental 
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Figure 2 Sputum inflammatory mediators in patients with asthma and COPD having phenotypes for (A) eosinophilic airway inflammation and (B) non-eosinophilic airway 
inflammation. Horizontal and error bars set at geometric mean and 95% confidence interval.
Notes: Reproduced with permission from S. Karger AG, Basel, Switzerland. Copyright ©2012 Bafadhel M, McCormick M, Saha S, et al. Profiling of sputum inflam matory 
mediators in asthma and chronic obstructive pulmonary disease. Respiration. 2012;83(1):36–44.53
Abbreviations: CCL, CC chemokine ligand; CXCL, CXC chemokine ligand; IL, interleukin; MMP, matrix metallopeptidase; TNF, tumor necrosis factor; TNFR, tumor 
necrosis factor receptor; veGF, vascular endothelial growth factor.
Table 2 Clinical and pathological similarities between asthma and COPD
Feature Asthma COPD
Thickened airway smooth muscle layer Yes Yes (minimally)
Inflammation involving goblet cells Yes Yes
Increased neutrophils in sputum Yes (severe asthma) Yes
Increased eosinophils in airways Yes Yes (steroid-sensitive COPD)
Increased CXC chemokine 8 Yes (severe asthma) Yes
Increased TNF Yes (severe asthma) Yes
Increased leukotriene B4 Yes (severe asthma) Yes
Oxidative stress Yes (severe asthma) Yes
Notes: Data from Barnes52 and Nakawah et al.60
Abbreviation: TNF, tumor necrosis factor.
stimuli, including allergens, cigarette smoking, air pol-
lution, and respiratory infections, particularly those 
of viral origin.64 Indeed, exacerbations in asthma and 
COPD are often triggered by common factors, including 
respiratory viruses during the autumn/winter months,65 
gastroesophageal reflux disease,66 and also comorbidities, 
although the specific comorbidities differ between the two 
conditions.33,67
While a smaller proportion of patients with asthma are 
smokers or ex-smokers than among patients with COPD, 
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smoking has negative consequences for both diseases in 
relation to morbidity, mortality, disease control, and response 
to medication.68,69
Asthma and COPD overlap syndrome
The recently revised GINA asthma guidelines include consensus 
guidance, developed in conjunction with GOLD, on the identi-
fication and differential diagnosis of ACOS.49 Characterized by 
moderate airflow limitation, pronounced but incomplete revers-
ibility, and no or very little emphysema, ACOS is ill-defined 
and may be difficult to treat because medications have not been 
evaluated in ACOS-specific randomized trials.62 The prevalence 
of ACOS varies according to geographic region and clinical 
setting (primary care or specialist practice), and is believed to be 
high, partly because of a lack of consistent diagnosis (Figure 3). 
A survey of Italian patients with physician-diagnosed asthma, 
COPD, or ACOS revealed that among those diagnosed with 
asthma, 16%–61% also had ACOS, while for those diagnosed 
with COPD, 25%–33% also had ACOS, with the incidence 
varying according to age group.70
Patients with ACOS tend to be older than those with asthma, 
they have a significant smoking history, present with asthmatic 
features to their COPD, and have persistent airflow limitation.49,61 
Physicians need to be able to differentiate between asthma, 
COPD, and ACOS so that patients receive the most appropriate 
treatment. For instance, the response to inhaled corticosteroids 
and β
2
-agonists is superior in patients with features of both 
COPD and asthma than in those only with features of COPD;71 
however, exacerbation frequency and severity is worse in the 
population with overlapping symptoms, although the progres-
sion in terms of FEV
1
 decline may be slower than in COPD.72,73 
Guidelines are intended to help improve the accurate diagnosis 
of each condition and ensure patients receive individualized 
treatment.49,74 Patients with this phenotype have most likely 
an enhanced response to inhaled corticosteroids, owing to the 
presence of eosinophilic bronchial inflammation.75–77
Future management of COPD: 
recognition of treatable traits
COPD is a complex heterogeneous disease where assess-
ment and management have traditionally been based on the 
severity of airflow limitation measured as FEV
1
. However, 
it is now recognized that FEV
1
 does not describe the com-
plexity of the disease and that other factors need to be 
measured to fully assess this condition. More recently, the 
GOLD strategy document has proposed a combined assess-
ment using three variables: symptoms, airflow limitation, 
and exacerbations.2 Phenotypes like frequent exacerbators, 
patients with predominant emphysema, and patients with 
overlapping characteristics of asthma and COPD warrant 
specific treatments. In addition, it has been proposed that 
in the future more variables should be added to the assess-
ment that reflect the three domains of disease severity, 
activity, and impact (Figure 4).78 For example, evaluation 
/DFNRIFRQVLVWHQF\LQGDLO\FOLQLFDOSUDFWLFHLQSDUWLFXODUZLWKUHJDUGWRFRGLQJ
6\VWHPDWLFHUURUVLQWKHGLDJQRVWLFSURFHGXUH
'LDJQRVWLFFRQIXVLRQ
0HGLFDWLRQSUHVFULSWLRQVHJSDWLHQWVZLWK&23'PD\EHOLHYHWKH\KDYHDVWKPDEHFDXVHWKH\KDYHEHHQSUHVFULEHGDVWKPDPHGLFDWLRQ
0LVXQGHUVWDQGLQJHJWKHUHVXOWVRIGLDJQRVWLFSURFHGXUHVRUKHWHURJHQHLW\LQV\PSWRPV
,PSUHFLVHLQIRUPDWLRQLQWH[WERRNVDQGJXLGHOLQHV
Figure 3 Potential reasons for the high prevalence of overlap between COPD and asthma. 
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of the disease severity domain could include assessment of 
arterial oxygen pressure, the IC/TLC ratio, and 6MWD in 
addition to more standard measures such as FEV
1
.78 Each of 
the domains will provide information on different aspects of 
the disease with a potential influence on clinical outcomes or 
potentially requiring specific targeted therapy, and provides 
a route towards personalized medicine for COPD.
Thus, regardless of the diagnostic labeling, which may 
change over time, the authors of this review believe that patients 
with COPD should be assessed beyond FEV
1
 and treated 
according to their individual clinical characteristics. Although 
this approach introduces complexity into the treatment algo-
rithm and departs from the “one size fits all” treatment based on 
the level of FEV
1
, it is likely to improve the clinical outcomes 
in most of the patients with the label of COPD.
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